en · de · es · fr · pt
glossary-desk.peptides7250.com › Faq › Research Literature And Evidence Status — What the Evidence Shows

Research Literature And Evidence Status — What the Evidence Shows

By Editorial Desk · published 2026-07-29 · last reviewed 2026-08-01 · Faq

counterion comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Research Literature and Evidence Status

Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.

Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.

Handling, Stability, and Quality Checks

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.

BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.

The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.

Bpc-157 at a glance

PropertyValueNotes
Main study modelRodents, rats and miceUnderpins most of the published data
Common routes in studiesSubcutaneous, intraperitoneal, oralVaries with the experimental design
Common analytical methodReversed-phase HPLC, LC-MSUsed for identity and purity checks
Human evidence baseSmallFew trials reported, with limited findings
Regulatory statusVaries by jurisdictionNot an approved medicine in most places

Background and Molecular Identity

Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.

BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.

Related pages on this site

BPC-157 Origin and Structure

Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.

Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.

BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.

Supporting material

=== Alcohol use === GGT is elevated by ingestion of large quantities of alcohol. However, determination of high levels of total serum GGT activity is not specific to alcohol intoxication, and the measurement of selected serum forms of the enzyme offer more specific information. Isolated elevation or disproportionate elevation compared to other liver enzymes (such as ALT or alanine transaminase) can indicate harmful alcohol use or alcoholic liver disease, and can indicate excess alcohol consumption up to 3 or 4 weeks prior to the test. The mechanism for this elevation is unclear. Alcohol might increase GGT production by inducing hepatic microsomal production, or it might cause the leakage of GGT from hepatocytes.

=== Hyperthermia therapy === Hyperthermia therapy is heat treatment for cancer that can be a powerful tool when used in combination with chemotherapy (thermochemotherapy) or radiation for the control of a variety of cancers. The heat can be applied locally to the tumor site, which will dilate blood vessels to the tumor, allowing more chemotherapeutic medication to enter the tumor. Additionally, the tumor cell membrane will become more porous, further allowing more of the chemotherapeutic medicine to enter the tumor cell. Hyperthermia has also been shown to help prevent or reverse "chemo-resistance." Chemotherapy resistance sometimes develops over time as the tumors adapt and can overcome the toxicity of the chemo medication. "Overcoming chemoresistance has been extensively studied within the past, especially using CDDP-resistant cells. In regard to the potential benefit that drug-resistant cells can be recruited for effective therapy by combining chemotherapy with hyperthermia, it was important to show that chemoresistance against several anticancer drugs (e.g. mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat.

In this approach, a recognition site at polymer is offered to non-covalently anchor the monomer at polymer chain, which can subsequently go through a chemical insertion into polymeric backbone. One successful example demonstrates that methacrylic acid (monomer) can be radically incorporated into a backbone featuring a recognizable cationic site (protonated primary amine pendant). Driven by this site-specific reaction, the sequence-controlled polymerization can be achieve by using a template adorned with differenrt recognizable pendants.

The preceding beta blockers also vary in their intrinsic sympathomimetic activity and β1-adrenergic receptor selectivity (or cardioselectivity), resulting in further differences in pharmacological profiles and suitability in different contexts between them. The brain-to-blood ratios of certain beta blockers in humans have been characterized and have been found to be 50:1 for oxprenolol, 15:1 to 33:1 for propranolol, 16:1 for alprenolol, 12:1 for metoprolol, and 0.2:1 for atenolol. The blood-to-brain ratios of various other beta blockers, for instance acebutolol, bevantolol, nadolol, pindolol, and timolol, appear to be unknown.

dadantii must overcome obstacles, such as defense barriers, secondary metabolites and toxic materials. An example of a plant defense mechanism is to produce a defensive barrier, such as a cork layer. However, when the infection is spread by larvae, the cork layer is eaten as quickly as it is made by the plant. Consequently, the protective cork layer is an ineffective protection mechanism. The bacteria continue to spread and multiply throughout the plant, moving in the intercellular spaces, within collapsed cells and the xylem. As the bacteria grow in numbers, additional hosts are infected through the spread of bacteria by: splashing water from infected plants, insects, and cultural practices including the use of contaminated tools, gloves and machinery and improper storage of cultivated crops or seeds. D. dadantii can be a problem year round, given the right environmental conditions exist. It is able to infect plants in greenhouses, indoor interiorscapes and tropical areas where temperatures and humidity remains high. At higher latitudes, infections are mainly during the hot and humid summer months.

Sources: en.wikipedia.org

Supporting material

Helena was an art installation by Marco Evaristti originally at the Trapholt museum in 2000. The art consisted of a room with 10 blenders, each of which contained a green swordtail (often misreported as goldfish). The fish were vulnerable to any visitor to the exhibit who chose to turn on a blender and kill them. During the exhibition two fish were killed in this way. Persons present at the initial exhibition of the installation noted that "numerous media representatives who were present... virtually encouraged the visitors to press the button in order to initiate a scandal". Legal complaints resulted in the blenders being unplugged, though the installation remained on display.

=== EC 2.3.3: Acyl groups converted into alkyl on transfer === EC 2.3.3.1: citrate (Si)-synthase EC 2.3.3.2: decylcitrate synthase EC 2.3.3.3: citrate (Re)-synthase EC 2.3.3.4: decylhomocitrate synthase EC 2.3.3.5: 2-methylcitrate synthase EC 2.3.3.6: 2-ethylmalate synthase EC 2.3.3.7: 3-ethylmalate synthase EC 2.3.3.8: ATP citrate synthase EC 2.3.3.9: malate synthase EC 2.3.3.10: hydroxymethylglutaryl-CoA synthase EC 2.3.3.11: 2-hydroxyglutarate synthase EC 2.3.3.12: 3-propylmalate synthase EC 2.3.3.13: 2-isopropylmalate synthase EC 2.3.3.14: homocitrate synthase EC 2.3.3.15: sulfoacetaldehyde acetyltransferase EC 2.3.3.16: citrate synthase (unknown stereospecificity) EC 2.3.3.17: methylthioalkylmalate synthase EC 2.3.3.18: 2-phosphinomethylmalate synthase EC 2.3.3.19: 2-phosphonomethylmalate synthase EC 2.3.3.20: acyl-CoA:acyl-CoA alkyltransferase

== Data collection == Protein NMR utilizes multidimensional nuclear magnetic resonance experiments to obtain information about the protein. Ideally, each distinct nucleus in the molecule experiences a distinct electronic environment and thus has a distinct chemical shift by which it can be recognized. However, in large molecules such as proteins the number of resonances can typically be several thousand and a one-dimensional spectrum inevitably has incidental overlaps. Therefore, multidimensional experiments that correlate the frequencies of distinct nuclei are performed. The additional dimensions decrease the chance of overlap and have a larger information content, since they correlate signals from nuclei within a specific part of the molecule. Magnetization is transferred into the sample using pulses of electromagnetic (radiofrequency) energy and between nuclei using delays; the process is described with so-called pulse sequences. Pulse sequences allow the experimenter to investigate and select specific types of connections between nuclei. The array of nuclear magnetic resonance experiments used on proteins fall in two main categories — one where magnetization is transferred through the chemical bonds, and one where the transfer is through space, irrespective of the bonding structure. The first category is used to assign the different chemical shifts to a specific nucleus, and the second is primarily used to generate the distance restraints used in the structure calculation, and in the assignment with unlabelled protein.

In sufficient amounts, the theobromine found in chocolate is toxic to animals such as cats, dogs, horses, parrots, and small rodents because they are unable to metabolize the chemical effectively. If animals are fed chocolate, the theobromine may remain in the circulation for up to 20 hours, possibly causing epileptic seizures, heart attacks, internal bleeding, and eventually death. Medical treatment performed by a veterinarian involves inducing vomiting within two hours of ingestion and administration of benzodiazepines or barbiturates for seizures, antiarrhythmics for heart arrhythmias, and fluid diuresis. A typical 20-kilogram (44 lb) dog will normally experience great intestinal distress after eating less than 240 grams (8.5 oz) of dark chocolate, but will not necessarily experience bradycardia or tachycardia unless it eats at least a half a kilogram (1.1 lb) of milk chocolate. Dark chocolate has 2 to 5 times more theobromine and thus is more dangerous to dogs. According to the Merck Veterinary Manual, approximately 1.3 grams of baker's chocolate per kilogram of a dog's body weight (0.02 oz/lb) is sufficient to cause symptoms of toxicity. For example, a typical 25-gram (0.88 oz) baker's chocolate bar would be enough to bring about symptoms in a 20-kilogram (44 lb) dog. In the 20th century, there were reports that mulch made from cocoa bean shells is dangerous to dogs and livestock.

== Bibliography == Allport, Alan (2015). Browned Off and Bloody-minded: The British Soldier Goes to War 1939–1945. New Haven: Yale University Press. ISBN 978-0-300-17075-7. Beckett, Ian F. W. Territorials: A Century of Service, first published April 2008 by DRA Printing of 14 Mary Seacole Road, The Millfields, Plymouth PL1 3JY on behalf of TA 100, ISBN 978-0-9557813-1-5 Bell, P. M. H. (1997) [1986]. The Origins of the Second World War in Europe (2nd ed.). London: Pearson. ISBN 978-0-582-30470-3. Campbell, John (2020). Haldane: The Forgotten Statesman Who Shaped Modern Britain. London: Hurst & Co. Dennis, Peter (1987). The Territorial Army. Woodbridge: The Royal Historical Society: Boydell Press.{{cite book}}: CS1 maint: publisher location (link) Dunlop, John K (1938). The development of the British Army 1899–1914. London: Methuen. Frederick, J. B. M. (1984). Lineage book of British land forces 1660-1978 : biographical outlines of cavalry, yeomanry, armour, artillery, infantry, marines and air force land troops of regular and reserve forces (Volume I). Wakefield: Microform Academic. ISBN 978-1-85117-007-4. OCLC 18072764. French, David (2001) [2000]. Raising Churchill's Army: The British Army and the War Against Germany 1919–1945. Oxford: Oxford University Press. ISBN 978-0-199-24630-4. Gibbs, N. H. (1976). Grand Strategy. History of the Second World War. Vol. I. London: HMSO. ISBN 978-0-116-30181-9. Gregory, Barry (2006). A History of the Artists Rifles 1859-1947. Barnsley: Pen and Sword. Heyman, M. A.

Sources: en.wikipedia.org

Frequently asked questions

What kinds of studies dominate this field?

Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.

Are the reported mechanisms established facts?

They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.

How is the compound regulated?

Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.

How is a lyophilised peptide powder stored?

Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.

Network